About AcuamarkDx
AcuamarkDx is a company based in New York (United States) founded in 2013. AcuamarkDx has raised $20.01 million across 4 funding rounds from investors including Bruker and Claudio Del Vecchio. AcuamarkDx offers products and services including qPCR Cancer Assay. AcuamarkDx operates in a competitive market with competitors including Guardant Health, GRAIL, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Acuamark Diagnostics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20.01 M (USD)
in 4 rounds
-
Latest Funding Round
$4.94 M (USD), Series A
May 22, 2024
-
Investors
Bruker
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AcuamarkDx
AcuamarkDx offers a comprehensive portfolio of products and services, including qPCR Cancer Assay.
Technology for detecting early-stage cancer markers in blood samples.
Funding Insights of AcuamarkDx
AcuamarkDx has successfully raised a total of $20.01M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $4.94 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AcuamarkDx
AcuamarkDx has secured backing from 2 investors, including angel and institutional investors. Prominent investors backing the company include Bruker and Claudio Del Vecchio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified research instrument systems are manufactured and supplied.
|
Locked | Locked | Locked | |
|
CD
Claudio Del Vecchio |
-
|
Locked | Locked | Locked |
Investor details for AcuamarkDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AcuamarkDx
Investment portfolio details for AcuamarkDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AcuamarkDx
Detailed financials for AcuamarkDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Acuamarkdx Comparisons
Peer comparison for AcuamarkDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AcuamarkDx
AcuamarkDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Delfi Diagnostics, BillionToOne and Thrive Earlier Detection, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
|
| Locked | Locked | Locked |
Provider of cell-free cancer liquid biopsy test
|
|
| Locked | Locked | Locked |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
|
| Locked | Locked | Locked |
MicroRNA profiling platform is developed to detect genes in samples.
|
Detailed competitors of AcuamarkDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Acuamarkdx
Complete news archive for AcuamarkDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AcuamarkDx
AcuamarkDx was founded in 2013 and raised its 1st funding round 3 years after it was founded.
AcuamarkDx is headquartered in New York, United States. It is registered at New York, New York, United States.
AcuamarkDx is a funded company, having raised a total of $20.01M across 4 funding rounds to date.
Provider of non-invasive screening test for early detection of cancer. The proprietary Eagle iSEQ is a deep sequencing analytic tool that enables targeted deep sequencing of DNA from blood and is compatible with existing instrumentation. The Eagle i5 suite of assays detects multiple cancer markers, including gene mutation, methylation, exosomal miRNA, lncRNA and mRNA, translocations, and splice variants. The first application is colorectal cancer, but the company plans to expand to a pan-cancer assay.
AcuamarkDx's top competitors include Guardant Health, GRAIL and BillionToOne.
AcuamarkDx offers qPCR Cancer Assay.
AcuamarkDx has 2 investors. Key investors include Bruker, and Claudio Del Vecchio.